Clinical Trial Update: Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 trial evaluating the RAD combination (lenalidomide, doxorubicin, dexamethasone) in relapsed or refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Adriamycin (doxorubicin)
• Decadron (Dexamethasone)
• Revlimid (lenalidomide)

Snippet

Sponsor: University of Wuerzburg | Conditions: Relapse, Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED